Promising results for triple A1/A2A/A2B adenosine receptor antagonist in cancer immunotherapy April 15, 2021
Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor April 14, 2021
Bile acid sequestrant SAR-442357 improves experimental type 2 diabetes and comorbidities April 7, 2021
Yhhu-2407, novel low systemic DGAT1 inhibitor with potential for the treatment of dyslipidemia March 31, 2021
RSS